Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Alvarado M, Julian BQ, Ewing C, Wong J, Rose J, Esserman L, Foster R, Mukhtar RA. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast
— 2025cited by 0position: selected
Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunothera
— 2025cited by 0position: selected
Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial
Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes. Cancer Epidemiol Biomarkers Prev. 2023 08 01;
— 2023cited by 0position: selected
Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy. Ann Surg Oncol. 2023 Oct; 30(10):5999-6006.
— 2023cited by 0position: selected
Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes. Plast Reconstr Surg Glob Open. 2023 Jan; 11(1):e4767.
— 2023cited by 0position: selected
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies. Am J Surg. 2022 04; 223(4):699-704.
— 2022cited by 0position: selected
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. NPJ Breast Cancer. 2021 Mar 05; 7(1):25.
— 2021cited by 0position: selected
Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives. Breast J. 2021 04; 27(4):406-408.
— 2021cited by 0position: selected
Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Ann Surg Oncol. 2021 May; 28(5):2555-2560.
— 2021cited by 0position: selected
Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater. Am J Surg. 2021 01; 221(1):32-36.
— 2021cited by 0position: selected
Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2020 Oct; 183(3):661-667.
— 2020cited by 0position: selected
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy
Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?
The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander–Implant Exchange in Prosthetic Breast Reconstruction
Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.
Immediate Implant-Based Breast Reconstruction following Total Skin-Sparing Mastectomy
Total Skin-Sparing Mastectomy and Immediate Breast Reconstruction: An Evolution of Technique and Assessment of Outcomes
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
Total Skin-Sparing Mastectomy in BRCA Mutation Carriers
Outcomes after Total Skin-sparing Mastectomy and Immediate Reconstruction in 657 Breasts
The Effects of Acellular Dermal Matrix in Expander-Implant Breast Reconstruction after Total Skin-Sparing Mastectomy